Benchmarking AIDS - Pharmaceutical Executive

ADVERTISEMENT

Benchmarking AIDS
Pharma is taking on the global AIDS crisis. But who has crafted the best approach? The Interfaith Center on Corporate Responsibility defines best practices and matches major companies head-to-head. Grades are posted inside.


Pharmaceutical Executive


To date, Merck has issued a license to Aspen Pharmacare, and also to Thembalami, a joint venture of Adcock and Ranbaxy. But when Thembalami dissolved, observers expected Merck to issue the two parent companies licenses—that has not happened. Merck will be under increasing pressure to issue voluntary licenses because several generic companies recently lowered prices on efavirenz in an agreement with the Clinton Foundation. Making those price cuts widely available may require additional licenses.

[Drug Discovery]




Novartis may make a significant contribution to the fight against neglected diseases with its Novartis Institute for Tropical Diseases (NITD), a public-private drug-discovery partnership between Novartis and the Singapore Economic Development Board, which is aimed at major tropical diseases. Other areas of research score high as well: It played a leading role in developing antimalarial FDCs, including Coartem, and has developed two of the three products in the multi-drug therapy used in WHO's strategy to eliminate leprosy.

Novartis is committed to providing the leprosy treatment for free, and is planning no-profit pricing for drugs resulting from NITD research. However, it is unclear if NITD-developed drugs will be licensed, since the research is still in early stages. But, given the promise of this venture, the company should explore licensing and technology transfer as tools for developing essential patented medicines beyond ARVs.

[Industry Leader?]




Pfizer has immense resources which could bring research-based and market-based solutions to bear on the issue of medicine access. However, the firm is heavily dependent on traditional philanthropic approaches to health problems and conducts little research for the developing world. Given Pfizer's disproportionate influence on the industry, these issues are especially troubling.

Pfizer's most notable program is its Diflucan donation program. Pfizer now gives the anti-fungal medication to 21 countries with an HIV prevalence above one percent without a time limit on the donation. However, critics argue that differential pricing and licensing would have been superior alternatives. The Diflucan effort specifically has been criticized for its red tape, narrow focus, and insufficient geographic reach. The company also has employee-volunteer programs and supports healthcare infrastructure development in Uganda. There are no further neglected-disease drugs in the company pipeline. However, Pfizer clearly sees a core business case for action, since it has devoted immense PR resources to addressing issues surrounding access to medicine in the developing world.

[Patent Prowess]




Roche manufactures several ARVs, and is heavily invested in HIV research. However, it has not worked with other companies to create FDCs—particularly for Fortovase, which should be taken with Norvir. The company has even stayed away from blister packaging its products, citing IP and liability issues. It also produces other drugs, like Fuzeon, the first fusion inhibitor—a twice-daily subcutaneous injection that costs $20,000 per year—which is not even remotely accessible to patients in the developing world. Roche has clear patent policies, and has pledged not to file patents on ARVs or malaria drugs in the least-developed countries. Recently, Roche announced a technology-transfer initiative to provide local manufacturers with the technical expertise to produce Invirase, a WHO-recommended treatement.

Roche must also be commended for its predictable, transparent pricing in both LDC and middle-income countries. However, some critics express concern that prices remain way too high in middle-income countries, and that the disparity between pediatric and adult formulations is too great.


ADVERTISEMENT

blog comments powered by Disqus
UPCOMING CONFERENCES

Serialization Summit
San Diego, CA
Feb. 27-28, 2014



Advances in Aseptic Processing
San Diego, CA
Mar. 10-12, 2014



ClinTech 2014
Cambridge, MA
Mar. 11-13 2014


Investigator-Initiated and
Sponsored Research (IISR)

Philadelphia, PA
Mar. 19-20 2014

See All Conferences >>

Source: Pharmaceutical Executive,
Click here